Active, not recruitingPhase 3NCT02506153
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
Studying Germ cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Sapna PatelSWOG Cancer Research Network
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 1301 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2027
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Cancer Center at Saint Joseph's, Phoenix, Arizona, United States
- Virginia G Piper Cancer Care-Del Camino, Scottsdale, Arizona, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Highlands Oncology Group - Rogers, Rogers, Arkansas, United States
- Kaiser Permanente-Anaheim, Anaheim, California, United States
- Sutter Auburn Faith Hospital, Auburn, California, United States
- Kaiser Permanente-Baldwin Park, Baldwin Park, California, United States
- Kaiser Permanente-Bellflower, Bellflower, California, United States
- UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Kaiser Permanente-Fontana, Fontana, California, United States
- Kaiser Permanente-Fremont, Fremont, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02506153 on ClinicalTrials.govOther trials for Germ cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07552233NK Cell Therapy for Malignant Solid Brain TumorsPeking University Third Hospital
- RECRUITINGNCT07314164Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior TreatmentIpsen
- RECRUITINGPHASE1NCT07143812A Study to Evaluate the Safety of a Stem Cell-Based Gene and Cell Therapy in Patients With Newly Diagnosed GlioblastomaCHA University
- RECRUITINGNANCT06910306Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent GlioblastomaAlpha Tau Medical LTD.
- RECRUITINGNANCT07459101UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4Sunnybrook Health Sciences Centre
- RECRUITINGPHASE1, PHASE2NCT07193966NG2 and DLL3 CAR-T Cells Targeting MelanomaShenzhen Geno-Immune Medical Institute
- RECRUITINGPHASE2NCT06712927Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesStanford University
- RECRUITINGPHASE1, PHASE2NCT06712875MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric GliomasAnn & Robert H Lurie Children's Hospital of Chicago